

Alpha Teknova, Inc. (TKNO)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001850902

Alpha Teknova, Inc. TKNO; healthcare	
Grade	D fourth fifth of 371 graded peers percentile 64.3; sampling error 2.5 points; lower is stronger
Rank	239 of 371
Profitability	D percentile 69.0
Solvency	B percentile 36.9
Growth and financing	C percentile 53.3
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$103.6M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	9 of 14
Graded from	filings received through Mar 2, 2026 221 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$8.45 2026-10-08; market equity \$453.7M
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Mar 21, 2025, D from Mar 21, 2026

Letter at every rescanscan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 2, 2026

Alpha Teknova, Inc. (referred to herein as the Company, Teknova, we, us or our) is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our Company is built around our knowledge, methods, and know-how in our manufacturing processes and infrastructure, which are

highly adaptable and configurable.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 69.0						
Gross profitability		13.0%	32.2%	71.7	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(7.7%)	(6.6%)	51.0	811	2025-12-31
Gross margin stability, five years		10.1 pts	2.8 pts	84.3	243	2025-12-31
Solvency, sleeve percentile 36.9						
Twelve-month failure probability		0.04%	0.07%	26.7	248	2026-06-30
Altman Z double-prime		(1.59)	(0.31)	43.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		4.58x	2.96x	40.3	839	2025-12-31
Growth and financing, sleeve percentile 53.3						
Revenue growth, three-year compound		(0.7%)	10.0%	73.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(12.1%)	2.1%	71.4	704	2025-12-31
Net share issuance, one year		0.3%	2.5%	15.3	634	2026-02-27

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
234	Lenz Therapeutics, Inc. (LENZ)	63.0	D	short runway
235	AbbVie Inc. (ABBV)	63.2	D	
236	Caribou Biosciences, Inc. (CRBU)	63.5	D	short runway
237	Royalty Pharma plc (RPRX)	63.8	D	
238	Integra Lifesciences Holdings Corp. (IART)	64.1	D	
239	Alpha Teknova, Inc. (TKNO) <	64.3	D	
240	Arvinas, Inc. (ARVN)	64.6	D	short runway, fortress balance sheet
241	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
242	Fulgent Genetics, Inc. (FLGT)	65.1	D	short runway
243	Entera Bio Ltd. (ENTX)	65.4	D	degenerate inputs
244	Dentsply Sirona Inc. (XRAY)	65.7	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	16.0%	8.0%	56
Distance from 52-week high	(9.5%)	(31.4%)	85
EBIT to enterprise value	(3.7%)	(1.5%)	44
Free cash flow yield	(2.2%)	(1.0%)	47
Book value to price	0.14	0.28	34
Sales to price	0.09	0.31	23
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.06)	(0.14)	56

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$6.0M
Operating cash flow, four quarters	-\$6.3M

Months of runway	11.5
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$1.2M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$13.4M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
2	assets	us-gaap:Assets	\$103.6M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
3	operating income	us-gaap:OperatingIncomeLoss	-\$17.0M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$11.7M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$58,000	2025-12-31	2026-03-02	10-K	0001850902-26-000002
6	total debt	us-gaap:LongTermDebt	\$13.1M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
7	book equity	us-gaap:StockholdersEquity	\$68.8M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$5.9M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
9	total debt	us-gaap:LongTermDebt	\$9.4M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
10	book equity	us-gaap:StockholdersEquity	\$82.4M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.7M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
12	net income	us-gaap:NetIncomeLoss	-\$17.3M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$8.6M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
14	assets	us-gaap:Assets	\$118.8M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$40.5M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
16	gross profit	us-gaap:GrossProfit	\$7.2M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$37.7M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
18	gross profit	us-gaap:GrossProfit	\$10.3M	2023-12-31	2025-03-07	10-K	0000950170-25-035705
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$36.7M	2023-12-31	2025-03-07	10-K	0000950170-25-035705
20	gross profit	us-gaap:GrossProfit	\$17.5M	2022-12-31	2024-03-27	10-K	0000950170-24-036624
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$41.4M	2022-12-31	2024-03-27	10-K	0000950170-24-036624
22	gross profit	us-gaap:GrossProfit	\$17.6M	2021-12-31	2023-03-30	10-K	0000950170-23-010926
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$36.9M	2021-12-31	2023-03-30	10-K	0000950170-23-010926
24	current assets	us-gaap:AssetsCurrent	\$34.5M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
25	current liabilities	us-gaap:LiabilitiesCurrent	\$7.5M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$135.8M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
27	liabilities	us-gaap:Liabilities	\$34.8M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$6.3M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.1M	2025-12-31	2026-03-02	10-K	0001850902-26-000002
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$12.4M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.1M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$18.8M	2023-12-31	2025-03-07	10-K	0000950170-25-035705
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.9M	2023-12-31	2025-03-07	10-K	0000950170-25-035705
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.4M	2022-12-31	2024-03-27	10-K	0000950170-24-036624
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$28.1M	2022-12-31	2024-03-27	10-K	0000950170-24-036624
36	current assets	us-gaap:AssetsCurrent	\$42.8M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
37	current liabilities	us-gaap:LiabilitiesCurrent	\$11.2M	2024-12-31	2026-03-02	10-K	0001850902-26-000002
38	assets	us-gaap:Assets	\$128.6M	2023-12-31	2025-03-07	10-K	0000950170-25-035705
39	assets	us-gaap:Assets	\$152.3M	2022-12-31	2024-03-27	10-K	0000950170-24-036624
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,587,662	2026-02-27	2026-03-02	10-K	0001850902-26-000002
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,436,806	2025-03-05	2025-03-07	10-K	0000950170-25-035705